Last reviewed · How we verify

Etomidate Injectable Emulsion

Hunan Kelun Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Etomidate is a rapid-acting intravenous anesthetic that enhances GABAergic inhibitory neurotransmission in the central nervous system.

Etomidate is a rapid-acting intravenous anesthetic that enhances GABAergic inhibitory neurotransmission in the central nervous system. Used for Induction of general anesthesia, Sedation in intensive care settings.

At a glance

Generic nameEtomidate Injectable Emulsion
SponsorHunan Kelun Pharmaceutical Co., Ltd.
Drug classGABA-A receptor positive allosteric modulator; general anesthetic
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Etomidate acts as a positive allosteric modulator of GABA-A receptors, increasing the frequency of chloride channel opening and hyperpolarizing neuronal membranes. This results in rapid onset of unconsciousness suitable for induction of general anesthesia. The emulsion formulation improves tolerability and reduces injection site pain compared to traditional formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: